AKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Akari Therapeutics Plc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$9.89+1.71 (+20.90%)
Close on Oct 19, 2026
- Market cap
- $1.42T
- P/E (TTM)
- –
- Dividend yield
- –
Akari Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Akari Therapeutics | Industry median |
|---|---|---|
| Market Cap | $1.54T | $197.05M |
| Enterprise Value | $1.54T | $106.56M |
| PB Ratio | 82842.30 | 2.14 |
| P/TBV Ratio | 82842.30 | 2.46 |
Income (trailing twelve months)
| Measure | Akari Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$30.99M | -$21.44M |
| Pretax Income | -$32.82M | -$14.45M |
| Net Income | -$30.96M | -$22.46M |
| EBITDA | -$30.99M | -$16.91M |
| EPS (Diluted) | $0.00 | -$0.83 |
Returns
| Measure | Akari Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -140.1% | -53.1% |
| Return on Assets (ROA) | -69.2% | -41.0% |
| Return on Invested Capital (ROIC) | -144.9% | -32.0% |
| Return on Capital Employed (ROCE) | -125.5% | -37.8% |
Balance sheet
| Measure | Akari Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $7.69M | $62.42M |
| Net Cash (Debt) | $7.69M | $15.68M |
| Net Cash Per Share | $0.00 | $0.65 |
| Equity (Book Value) | $18.60M | $48.79M |
| Book Value Per Share | $0.00 | $1.36 |
| Tangible Book Value | $18.60M | $23.06M |
| Working Capital | -$5.61M | $75.77M |
Financial position
| Measure | Akari Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 0.60 | 3.30 |
| Quick Ratio | 0.55 | 2.39 |
| Interest Coverage | -128.59 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Akari Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$10.76M | -$12.35M |
Efficiency
| Measure | Akari Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$5.16M | -$732.08K |
| Employee Count | 6 | 73 |
Dividends and yields
| Measure | Akari Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -0.00% | -21.2% |
Shares
| Measure | Akari Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 155,759,000,000 | 59,128,900 |
| Shares Change (YoY) | 129.0% | 11.1% |
| Shares Change (QoQ) | 52.9% | 0.54% |
| Float | 119,438,000,000 | 48,744,500 |
| Shares Held by Insiders | 23.3% | 11.8% |
| Shares Held by Institutions | 0.00% | 59.4% |
Taxes
| Measure | Akari Therapeutics | Industry median |
|---|---|---|
| Income Tax | -$1.86M | $91.50K |
Scores
| Measure | Akari Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 46133.50 | 0.10 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Akari Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.